Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase II Clinical Trial of COVI-MSC in COVID-19 Patients with Persistent Pulmonary Compromise after Recovery (Long-Hauler)

Sorrento Therapeutics, Inc. announced receipt of clearance from ANVISA to proceed with a Phase IIa randomized, placebo-controlled study of intravenous allogeneic adipose-derived MSC to treat post COVID-19 “long haul” pulmonary compromise.